Jaydess (Levonorgestrel)

Levonorgestrel released from the device acts locally in the uterus. It thickens cervical mucus, impairs sperm motility, and creates endometrial changes that prevent implantation. In some cycles it may also suppress ovulation, together ensuring that fertilisation does not occur.

The dose of Jaydess is set by the prescribing clinician. The system contains 13.5 mg of levonorgestrel and releases approximately 20 µg per day, providing continuous contraceptive effect for up to three years after insertion.

Jaydess must not be used during an existing pregnancy; if pregnancy occurs, the device should be removed promptly. Limited data exist for breastfeeding, but the low systemic exposure generally poses minimal risk. Women should discuss individual circumstances with their healthcare provider.

To order Jaydess, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Jaydess and other levonorgestrel‑releasing IUSs such as Mirena share the same mechanism and high contraceptive efficacy. Jaydess contains a lower total hormone load (13.5 mg) and is approved for up to three years of use, whereas some alternatives contain higher doses and may be approved for five years, offering clinicians flexibility based on patient needs.

Jaydess should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme heat. Handling should be performed by trained healthcare professionals using aseptic technique during insertion.

Jaydess is inserted by a qualified healthcare professional into the uterine cavity through the cervical canal. The procedure is performed in a clinical setting using a sterile inserter. Once placed, the device remains effective without the need for daily user action.

Serious risks include uterine perforation during insertion, device expulsion or displacement, pelvic inflammatory disease, and the rare possibility of ectopic pregnancy if contraception fails. Prompt medical evaluation is essential if severe abdominal pain, abnormal bleeding or signs of infection develop.

Jaydess is contraindicated in women who are currently pregnant, have active pelvic infections, untreated cervical or uterine malignancies, unexplained vaginal bleeding, or known uterine anomalies that could impede device placement. Individuals with a history of severe allergic reaction to levonorgestrel should also avoid its use.